Abstract

A unique coagulopathy often manifests following traumatic brain injury, leading the clinician down a difficult decision path on appropriate prophylaxis and therapy. Conventional coagulation assays—such as prothrombin time, partial thromboplastin time, and international normalized ratio—have historically been utilized to assess hemostasis and guide treatment following traumatic brain injury. However, these plasma-based assays alone often lack the sensitivity to diagnose and adequately treat coagulopathy associated with traumatic brain injury. Here, we review the whole blood coagulation assays termed viscoelastic tests and their use in traumatic brain injury. Modified viscoelastic tests with platelet function assays have helped elucidate the underlying pathophysiology and guide clinical decisions in a goal-directed fashion. Platelet dysfunction appears to underlie most coagulopathies in this patient population, particularly at the adenosine diphosphate and/or arachidonic acid receptors. Future research will focus not only on the utility of viscoelastic tests in diagnosing coagulopathy in traumatic brain injury, but also on better defining the use of these tests as evidence-based and/or precision-based tools to improve patient outcomes.

Highlights

  • We provide a detailed description of the literature regarding the utility of viscoelastic tests (VET) in the diagnosis and treatment of coagulopathy of TBI (CTBI)

  • The management of CTBI patients is complicated by the scarcity of clinical data regarding the underlying pathophysiology and standard treatment strategies for CTBI [23,48,199,200]

  • Analysis of the benefits of VET-guided management of traumatic brain injury (TBI) and CTBI is in its infancy, yet it is important to acknowledge that significant gaps in knowledge persist

Read more

Summary

Incidence of Coagulopathy of Traumatic Brain Injury

Occult coagulopathy of traumatic brain injury (TBI) reportedly affects a high percent of trauma patients with a significant increase in morbidity [1,2,3,4,5,6]. Literature frequently cites an estimate that “one-third” of patients with a TBI will develop a coagulopathy of TBI (CTBI). The true incidence of coagulopathy reported in these patients has been cited as anywhere from 7 to 63%. This variability arises from the lack of consistency in the definition of coagulopathy and its causes in TBI. Comparisons of diagnosis and treatment among different populations of CTBI patients remain problematic [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41]

Implications of CTBI and Relation to VET-Based Definition
Inadequacy of Conventional Coagulation Assays in the Diagnosis of CTBI
Pathophysiology in CTBI and Its Relation to VETs
Guiding Blood Products with VETs in TBI
VET-Guided Diagnosis and Treatment of Platelet Dysfunction in TBI
Conclusions
Preinjury Antithrombotic Use
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call